CC
Therapeutic Areas
InflaRx Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vilobelimab (GOHIBIC) | Critical COVID-19 (SARS-CoV-2-induced ARDS) | Marketed (EUA) |
| Vilobelimab | Pyoderma Gangrenosum | Phase 3 |
| Izicopan (IFX-4) | Inflammatory Diseases | Preclinical |
| IFX002 | Inflammatory Diseases | Preclinical |
Leadership Team at InflaRx
PD
Prof. Dr. Niels C. Riedemann
Chief Executive Officer and Founder
PR
Prof. Renfeng Guo, M.D.
Chief Scientific Officer and Founder
DT
Dr. Thomas Taapken
Chief Financial Officer
JM
Jan Medina, CFA
Vice President, Head of Investor Relations
DO
Derval O’Carroll
Senior Vice President, Global Head of Regulatory Affairs & Compliance
DI
Dr. Igor Orshanskiy
Senior Director, Head of Business Development
NF
Nicolas Fulpius
Chairman of the Board